CelLBxHealth plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 sys… Read more
CelLBxHealth plc (CLBX) - Total Liabilities
Latest total liabilities as of December 2024: GBX7.02 Million GBX
Based on the latest financial reports, CelLBxHealth plc (CLBX) has total liabilities worth GBX7.02 Million GBX as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CelLBxHealth plc - Total Liabilities Trend (2021–2024)
This chart illustrates how CelLBxHealth plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CelLBxHealth plc Competitors by Total Liabilities
The table below lists competitors of CelLBxHealth plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cel AI PLC
LSE:CLAI
|
UK | GBX58.36K |
|
China Lending Corp
PINK:RAHGF
|
USA | $6.14 Million |
|
COTI
PINK:COTI
|
USA | $95.41K |
|
CNVISION MEDIA
BE:CBW
|
Germany | €5.64 Billion |
|
Core Nickel Corp.
V:CNCO
|
Canada | CA$56.73K |
Liability Composition Analysis (2021–2024)
This chart breaks down CelLBxHealth plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CelLBxHealth plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CelLBxHealth plc (2021–2024)
The table below shows the annual total liabilities of CelLBxHealth plc from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX7.02 Million | -14.88% |
| 2023-12-31 | GBX8.24 Million | -15.92% |
| 2022-12-31 | GBX9.80 Million | +40.37% |
| 2021-12-31 | GBX6.99 Million | -- |